Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | UNK | — |
Had redness; swelling reaction; This non-serious case was reported by a nurse via sales rep and described the occurrence of erythema in a adolescent female patient who received Men B NVS (Bexsero) for prophylaxis. Concomitant products included Meningococcal vaccine A/C/Y/W conj (CRM197) (Menveo). On an unknown date, the patient received Bexsero. On an unknown date, an unknown time after receiving Bexsero and an unknown time after receiving Menveo, the patient experienced erythema (Verbatim: Had redness) and swelling (Verbatim: swelling reaction). The outcome of the erythema and swelling were not reported. It was unknown if the reporter considered the erythema and swelling to be related to Bexsero and Bexsero Pre-Filled Syringe Device. It was unknown if the company considered the erythema and swelling to be related to Bexsero and Bexsero Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 27-MAR-2025 The patient was given a dose of Bexsero less than one week after Menveo was given. The reporter thought in the same arm. The patient had redness and swelling reaction. The parent thought that the patient had gotten a second dose of the same Meningitis vaccine.
Menveo